TABLE 3

Model comparison for effect of additional therapy on forced vital capacity over 36 months in patients with chronic hypersensitivity pneumonitis

	Model 1^#			Model 2^¶			Model 3⁺
	PRED cohort	No or additional therapy^§	p-value	PRED^ƒ cohort	No or additional therapy^§	p-value	PRED cohort	No or additional therapy^§	p-value
*PRED versus* no therapy**	−10.0±4.25%	−1.3±2.44%	0.042	−7.3±5.4%	−7.3±5.4%	0.999	−8.5±4.0%	−0.2±2.2%	0.036
*PRED versus* MMF**	−10.8±2.65%	−10.1±2.65%	0.864	−3.0±3.4%	−3.0±3.4%	0.999	−6.5±1.7%	−7.4±2.2%	0.708
*PRED versus* DMD**	−11.5±3.60%	−9.4±4.32%	0.585	−4.6±2.8%	−4.7±2.8%	0.999	−6.3±2.2%	−8.2±2.6%	0.644

Data are presented as mean±se change in forced vital capacity unless otherwise stated. PRED: prednisone; MMF: mycophenolate mofetil; DMD: disease-modifying drug (MMF or azathioprine). ^#: mixed-effects regression model estimates of change at baseline and at 36 weeks post-therapy; ^¶: difference-in-difference model estimates of change in slope before and after initiating steroid-sparing agent during the 36-week period; ⁺: shared parameter model jointly estimates of change at baseline and at 36 weeks post-therapy in addition to survival analysis in study cohort; ; ^§: additional therapy with steroid-sparing agent; ^ƒ: initiation of PRED monotherapy was associated with a mean forced vital capacity change of −7.3%.